**Salasar Exteriors & Contour Limited (SECL)** is an Indian listed entity currently undergoing a radical structural and operational transformation. Originally established in **2018** and listed on the **NSE SME ITP** platform in **September 2019**, the company is transitioning from a boutique interior design firm into a diversified conglomerate with interests in **Real Estate Trading**, **Pharmaceuticals**, and **AgriTech**. The company is presently pursuing a **Mainboard Listing on the NSE**, supported by a shift to a **zero-debt** status and a significant expansion of its authorized capital. --- ### **Strategic Pivot: Real Estate and Civil Operations** While historically rooted in civil and interior designing services, SECL has shifted its core focus toward **Real Estate Trading**. The company’s strategy involves acquiring interests in residential flats and land to capitalize on urban expansion. * **Geographic Concentration:** Operations are primarily centered in the **Mumbai suburban region**, specifically **Mira Road** and **Naigaon**. * **Expansion Targets:** The company is actively establishing a presence in new Mumbai suburban pockets and has recently expanded its corporate footprint to **Ahmedabad, Gujarat**. * **Legacy Services:** SECL continues to manage specialized sites involving labor, supervisors, and interior equipment, leveraging its historical expertise in civil works. --- ### **New Frontier: Agricultural Industry Diversification** In a major strategic shift, SECL has announced its entry into the **Agricultural Sector**, focusing on three high-growth pillars designed to create sustainable revenue streams: * **AgriTech Solutions:** Deploying technology to enhance on-field productivity. * **Agri Waste Management:** Developing sustainable farming practices and waste processing infrastructure. * **Agri Exports:** Targeting international markets to leverage India’s agricultural surplus. --- ### **Pharmaceutical Portfolio & Healthcare Strategy** SECL operates within the Indian pharmaceutical sector, targeting a market projected to reach **US$ 130 billion by 2030**. The company’s product strategy focuses on high-growth **chronic therapies** and innovative formulations. #### **Key Product Developments & Strategic Partnerships** | Product/Brand | Therapeutic Area | Significance | | :--- | :--- | :--- | | **Deuruxolitinib** | Dermatology (Alopecia) | Novel, oral **JAK1/2 inhibitor** (via Concert Pharma) | | **Akynzeo I.V.** | Oncology Support | First-in-India **I.V. formulation** for CINV (licensed from Helsinn) | | **Brillo (Bempedoic Acid)** | Cardiology | Non-statin therapy for **LDL cholesterol** reduction | | **Apatide (Apalutamide)** | Oncology (Prostate) | First generic version in India for metastatic cancer | | **Indacaterol + Mometasone** | Respiratory | First-to-market **Fixed-Dose Combination (FDC)** for Asthma | | **Medical Cannabis** | Alternative Medicine | Strategic entry into the **German medical market** | --- ### **Capital Structure & Financial Engineering** To facilitate its transition to the NSE Mainboard and fund new ventures, the company has overhauled its capital structure: * **Stock Split:** In **FY 2023-24**, equity shares were sub-divided from a **Face Value of ₹10** to **₹1**. * **Authorized Capital Expansion:** Proposed increase from **₹10.50 crore** to **₹26.50 crore** (representing **26.50 crore shares**). * **Fundraising:** Approved a **Rights Issue** to raise up to **₹49 crore**. * **Investment & Borrowing Limits:** Increased Section 186 limits to **₹50 crore** and enhanced borrowing powers to **₹50 crore**. * **Foreign Investment:** The aggregate limit for **FPIs and FIIs** has been increased to **49%** of paid-up capital. * **Debt Profile:** As of **October 2024**, the company has cleared all outstanding liabilities to achieve **zero-debt** status. --- ### **Corporate Governance & Leadership** The company has undergone significant administrative restructuring as of **2025**: * **Leadership:** **Mr. Shreekishan Joshi** has been re-appointed as **Managing Director** for a five-year term (**2025–2030**). * **Board Composition:** Comprises **4 Directors** (1 MD, 1 Non-Executive, 2 Independent). Recent appointments include **Mr. Haren Rathod** and **Mr. Sohilkumar Patel**. * **Office Relocation:** The Registered Office is shifting from **Maharashtra to Andheri East, Mumbai**, with a new Corporate Office established in **Ahmedabad, Gujarat**. * **Audit Oversight:** **M/s. Vishakha Agarwal & Associates** has been appointed as Secretarial Auditor through **FY 2029-30**. --- ### **Critical Risk Factors & Audit Qualifications** Investors should note that SECL faces severe regulatory and operational challenges. Statutory auditors issued a **Modified Opinion/Disclaimer of Opinion** for **FY 2024-25**, citing a pervasive lack of documentation. #### **Financial Discrepancies & Operational Risks** * **Verification Gaps:** Auditors were unable to verify **Fixed Asset Registers**, **Bank Statements**, or the genuineness of sales (lack of **E-Way bills** and **Delivery Challans**). * **Inventory Concerns:** Reported closing stock of **₹7.65 crore** lacks physical verification or a clear valuation basis. The company lacks owned/leased godowns. * **Unconfirmed Balances:** Significant liabilities remain unconfirmed, including **₹1,148.56 Lacs** in trade payables and **₹944.74 Lacs** in unconfirmed loans. * **IPO Mismanagement:** **₹1.7 crore** of IPO proceeds was transferred to **R.K. Manufacturing Co. Ltd.** as an advance; it remains unrecovered after four years with no provision for doubtful debt. #### **Regulatory & Compliance Summary** | Risk Area | Detail | | :--- | :--- | | **SEBI Investigation** | Investigation into financial misrepresentation for **FY 20-22**; penalty imposed **Oct 31, 2024**. | | **NPA Status** | Historical defaults on principal and interest; loans previously classified as **Non-Performing Assets**. | | **Statutory Defaults** | Non-compliance with **MSMED Act**; failure to appoint a woman director for nearly a year (**Aug 24 – July 25**). | | **GST Discrepancy** | Unreconciled **GST liability** of **₹15.85 Lacs**. | --- ### **Macro-Economic Alignment** SECL’s growth strategy is positioned to benefit from several Indian government initiatives: * **Steel:** National Steel Policy target of **30 crore tonnes** capacity by **2030-31**. * **Logistics:** National goal to reduce costs from **14% to 8% of GDP**. * **Pharma Exports:** Leveraging India’s **9.2% Y-o-Y export growth** and the **US$ 300 billion** bioeconomy target for 2030. * **Real Estate:** Capitalizing on the decentralization of IT/BFSI sectors into **Tier II & III cities**.